Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014 (MAR)
Sales Euro 203.1 million (2022: Euro 272.2 million, -25 %) Incoming orders Euro 166.9 million (2022: Euro 248.4 m…
Sales Euro 203.1 million (2022: Euro 272.2 million, -25 %) Incoming orders Euro 166.9 million (2022: Euro 248.4 m…
Net sales rose by 3.7% to EUR 836.1 million by the end of 2023 Adjusted EBITDA at EUR 154.6 million resulted in an adjus…
Organic revenue growth in 2023: +10.4% Organic adjusted EBITDA growth in 2023: +17.5% Favorable product mix boosts p…
The Supervisory Board and Executive Board of SAP SE (NYSE: SAP) recommend that shareholders approve a dividend of €2.20…
Final results 2022/23: Sales increase by 8% to EUR 488.0 million (2021/22: EUR 452.7 million); share of recurring r…
Annual Shareholders’ Meeting to be held on February 8, 2024 Main content of speeches to be given by Supervisory Board Ch…
Fresenius makes use of the governmental compensation and reimbursement payments of up to €300 million (from the curr…
Dr. Hakim Bouterfa, Executive Board member of Eckert & Ziegler AG and responsible for clinical development, will leave t…
Sales: Euro 157.5 million (previous year: Euro 205.2 million, -23 %) Incoming orders: Euro 128.3 million (previous y…
Robust demand continues in both divisions in the first nine months of 2023: order intake rises to € 6.2 billion Orde…